Softwr

Research · head to head

Genedata vs STARLIMS

Genedata logo

Genedata

Research

Enterprise R&D data platforms for biologics, screening and bioprocess, owned by Danaher

From
On request
Rated
-
STARLIMS logo

STARLIMS

Research

Laboratory information management from Abbott for regulated and public health labs

From
On request
Rated
-

The short version

  • Each has a real cost: Genedata there is no entry level and no published price at any tier, so a mid-sized biotech cannot even establish whether Genedata is in its range without a lengthy sales engagement.; STARLIMS implementation is lengthy and outcome quality depends heavily on the partner doing the configuration
  • They diverge on capability: Genedata covers Screener, STARLIMS covers Sample and specimen management.
  • Prices and features above were last checked on 31 August 2026.

Where they differ

Only the attributes on which Genedata and STARLIMS actually diverge.

Attributes where Genedata and STARLIMS differ
AttributeGenedataSTARLIMS
PlatformsWeb, On-premise, Private cloudWeb, Windows, Cloud, On-premise

Identical on both: starting price (On request), pricing model (quote), free tier (No), user rating (Not yet rated), category (Research).

What each one covers

Drawn from each product's published feature list. An absence here means we hold no record of it - not that the product lacks it.

Only in Genedata

  • Screener
  • Biologics
  • Bioprocess
  • Expressionist
  • Selector
  • Profiler
  • GxP-capable deployments

Only in STARLIMS

  • Sample and specimen management
  • Quality management
  • Public health reporting
  • Regulatory compliance
  • Web and mobile access

Both cover

  • Instrument integration

What people use each for

The jobs each tool is most often brought in to do.

Genedata

  • A pharmaceutical screening group processing thousands of plates a week where manual QC and curve fitting no longer scalenot STARLIMS
  • A biologics discovery team linking antibody sequence, expression and assay data across a campaign instead of in spreadsheetsnot STARLIMS
  • A process development group standardising bioprocess run data across sites for modelling and scale-upnot STARLIMS
  • A CRO delivering high-throughput screening results to sponsors that require documented, reproducible analysis pipelinesnot STARLIMS

STARLIMS

  • Public health laboratories handling surveillance and outbreak investigationnot Genedata
  • Clinical laboratories needing regulated specimen tracking and reportingnot Genedata
  • Food safety and environmental testing laboratoriesnot Genedata
  • Multi-site laboratory networks standardising methods and specificationsnot Genedata

Where each one falls short

Documented limitations, not opinions. Every one is a constraint you would hit in normal use.

Genedata

  • There is no entry level and no published price at any tier, so a mid-sized biotech cannot even establish whether Genedata is in its range without a lengthy sales engagement.
  • Platforms are licensed individually and most organisations need two or three, so the real contract is a sum of separate licences plus the integration work between them.
  • Deployment is a services programme rather than an installation, running months and requiring scientific configuration by the vendor, which means value arrives long after the first invoice.
  • Danaher ownership since 2023 gives the roadmap a natural pull toward Danaher instrument and bioprocessing lines, which is an advantage on that hardware and a question to ask if your instrument estate is from competitors.
  • Validated deployments for regulated use add scope, cost and an ongoing revalidation obligation on your side after each vendor release, and that recurring internal effort is rarely counted in the business case.

STARLIMS

  • Implementation is lengthy and outcome quality depends heavily on the partner doing the configuration
  • Pricing is quote-based with no public reference, making early budget setting difficult
  • The breadth across laboratory types means some verticals get less development attention than others
  • Interface modernisation has lagged behind newer cloud-native laboratory platforms
  • Over-specified for small laboratories, where a lighter LIMS delivers most of the value for a fraction of the effort

Pricing, plan by plan

Genedata

On request
  • Genedata platform licence$undefined/year
    • Each platform, such as Screener or Biologics, licensed separately
    • Annual enterprise subscription scoped on users, sites and data volume
    • Implementation and scientific configuration services quoted as a separate programme

STARLIMS

On request
  • STARLIMS$undefined/year
    • Sample management
    • Quality management
    • Instrument integration

Which should you pick?

Choose Genedata if

  • You need screener.
  • You work on Web, On-premise, Private cloud.
  • You also want biologics.

Choose STARLIMS if

  • You need sample and specimen management.
  • You work on Web, Windows, Cloud, On-premise.
  • You also want quality management.

Questions people ask

Is Genedata or STARLIMS better?
Neither clearly leads. Genedata starts at On request and STARLIMS at On request, and user ratings are close enough to be indistinguishable. Choose on capability and platform support.
Which is cheaper, Genedata or STARLIMS?
Genedata starts at On request and STARLIMS at On request.
Does Genedata or STARLIMS run on more platforms?
Genedata runs on Web, On-premise, Private cloud. STARLIMS runs on Web, Windows, Cloud, On-premise.
What is Genedata best used for?
Genedata is most often used for a pharmaceutical screening group processing thousands of plates a week where manual qc and curve fitting no longer scale, a biologics discovery team linking antibody sequence, expression and assay data across a campaign instead of in spreadsheets, a process development group standardising bioprocess run data across sites for modelling and scale-up, a cro delivering high-throughput screening results to sponsors that require documented, reproducible analysis pipelines. Of those, a pharmaceutical screening group processing thousands of plates a week where manual qc and curve fitting no longer scale and a biologics discovery team linking antibody sequence, expression and assay data across a campaign instead of in spreadsheets are not what STARLIMS is typically brought in for.
What can Genedata do that STARLIMS cannot?
Genedata covers Screener, Biologics, Bioprocess, Expressionist. STARLIMS covers Sample and specimen management, Quality management, Public health reporting, Regulatory compliance. Both handle Instrument integration.

Answered from the vendors’ own pages

Genedata: Who owns Genedata?

Danaher acquired the company in 2023. It remains headquartered in Basel and continues under the Genedata name.

STARLIMS: Who owns STARLIMS?

Abbott. That gives it institutional weight in laboratory procurement and a natural relationship with Abbott diagnostic instruments.

Genedata: Is there a small-team or starter option?

No. Everything is an enterprise contract scoped by users, sites and data volume, with services attached.

STARLIMS: Where is it strongest?

Public health and clinical laboratories. Surveillance reporting, outbreak investigation and unpredictable specimen surges are different problems from pharmaceutical QC, and it handles them well.

Genedata: Do I buy one product or the whole suite?

Each platform is licensed separately. Most customers license two or three and integrate between them.

STARLIMS: What does it cost?

Not published. Enterprise licensing plus implementation, quoted on laboratory count, users and modules.

Genedata: Can it be used in a GxP environment?

Yes, with a validated deployment contracted as additional scope. Ongoing revalidation after releases remains your responsibility.

STARLIMS: How does it compare to LabWare?

Both are enterprise LIMS with regulatory depth. LabWare is more dominant in pharmaceutical QC; STARLIMS has more presence in public health and clinical. Implementation partner quality matters more than the platform difference.

STARLIMS: What decides a successful implementation?

Configuration and validation quality, not platform features. Evaluations that compare feature lists rather than implementation approach are asking the wrong question.

Share

Related pages

Other head to heads